Kangmei Pharmaceutical Co., Ltd. (SHA:600518)

Market Cap	23.65B -19.2%
Revenue (ttm)	5.25B +1.2%
Net Income	10.33M +20.5%
EPS	0.00 +16.7%
Shares Out	13.83B
PE Ratio	2,289.64
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	157,677,102
Average Volume	159,961,730
Open	1.720
Previous Close	1.730
Day's Range	1.700 - 1.720
52-Week Range	1.690 - 2.270
Beta	0.76
RSI	37.60
Earnings Date	Apr 18, 2026

About Kangmei Pharmaceutical

Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese herbal medicines in China. The company offers Chinese patent medicines, chemical medicines, and health food products. In addition, it engages in the operation of Chinese medicinal materials markets; production and sale of medical devices; and operation of pharmaceutical logistics system. The company provides its products through medical institution resources, smart pharmacies, OTC retail, chain drug stores, direct sales, medical e-commerce, mobile medical care, etc. Kangmei Pharmaceuti...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 4,233
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600518

Financial Performance

In 2025, Kangmei Pharmaceutical's revenue was 5.25 billion, an increase of 1.22% compared to the previous year's 5.19 billion. Earnings were 10.33 million, an increase of 20.46%.